Egrifta (Tesamorelin) Complete Drug-Drug Interaction Profile

How Tesamorelin Works: Mechanism Relevant to Interactions

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile release of endogenous growth hormone (GH). That GH pulse then drives hepatic production of insulin-like growth factor 1 (IGF-1), which mediates the lipolytic effect on visceral adipose tissue [1].

The GH-IGF-1 Axis as an Interaction Gateway

Understanding the downstream cascade matters for predicting interactions. GH opposes insulin action at the hepatic and peripheral level, raising blood glucose. GH also stimulates cortisol-binding globulin synthesis, altering free cortisol dynamics. Any drug that independently modifies GH secretion, IGF-1 levels, glucose homeostasis, or cortisol metabolism has potential for a pharmacodynamic collision with tesamorelin.

Why Tesamorelin Lacks Classic CYP-Based Interactions

As a 44-amino-acid peptide, tesamorelin is degraded by nonspecific proteolytic enzymes rather than cytochrome P450 isoenzymes [2]. It does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. This means the classic interaction tables that dominate small-molecule pharmacology do not apply. The interaction profile is almost entirely pharmacodynamic, making it harder to detect through standard drug interaction software and easier to miss in clinical practice.

Antiretroviral Drug Interactions

Because tesamorelin is approved exclusively for HIV-associated lipodystrophy, every patient receiving it will also be on antiretroviral therapy (ART). This makes ART-tesamorelin interactions the single most common real-world scenario.

Protease Inhibitors: Ritonavir, Atazanavir, Darunavir

The FDA label notes that tesamorelin may alter the clearance of compounds metabolized by CYP3A4 indirectly, through GH-mediated changes in hepatic enzyme expression [2]. Endogenous GH is known to upregulate CYP3A4 activity in some contexts. Ritonavir-boosted regimens (ritonavir/darunavir, ritonavir/atazanavir) rely on ritonavir's CYP3A4 inhibition to maintain therapeutic protease inhibitor levels. A GH-driven increase in CYP3A4 activity could theoretically reduce boosted PI trough concentrations.

In the Phase III program studied by Falutz et al. (N=412), patients on stable ART (including PI-based regimens) did not show significant changes in HIV viral load during 26 weeks of tesamorelin treatment, suggesting that any CYP3A4 modulation was not clinically meaningful at the population level [1]. No formal pharmacokinetic crossover studies with specific PIs have been published.

Clinical recommendation: Monitor HIV viral load at baseline and 8-12 weeks after starting tesamorelin in patients on boosted PI regimens. No dose adjustment is required based on current evidence, but vigilance is appropriate.

NNRTIs: Efavirenz and Rilpivirine

Efavirenz is a CYP2B6 substrate and CYP3A4 inducer. The theoretical GH-mediated CYP3A4 upregulation adds a second induction signal, but published data from the Falutz trial showed no loss of viral suppression in NNRTI-treated patients [1]. Rilpivirine, a CYP3A4 substrate with a narrower therapeutic index than efavirenz, carries a slightly higher theoretical risk. No direct interaction data exist.

Integrase Inhibitors: Dolutegravir, Bictegravir, Cabotegravir

These agents are primarily metabolized by UGT1A1 with minor CYP3A4 contribution [3]. The risk of a tesamorelin interaction is low. No published case reports or pharmacokinetic studies document a clinically relevant signal.

Glucose-Lowering Agents: Insulin, Metformin, and Sulfonylureas

GH is a counter-regulatory hormone. It increases hepatic glucose output and reduces peripheral glucose uptake. This effect is the most consistently documented pharmacodynamic interaction in the tesamorelin literature.

Magnitude of the Glucose Effect

In the key Phase III trial, tesamorelin raised mean fasting glucose by approximately 4.3 mg/dL compared with placebo over 26 weeks (P=0.03) [1]. HbA1c increased by 0.12% in the tesamorelin group versus 0.04% in placebo [4]. Among patients with pre-existing impaired fasting glucose (100-125 mg/dL at baseline), a small subset progressed to overt diabetes. The Endocrine Society does not list tesamorelin among major diabetogenic drugs, but the FDA label carries a warning regarding glucose monitoring [2].

Impact on Insulin Therapy

Patients on basal insulin (glargine, degludec) or prandial insulin may require a dose increase of 5-15% after starting tesamorelin, based on extrapolation from GH-replacement literature [5]. No formal dose-adjustment algorithm for tesamorelin-insulin co-administration has been published.

Impact on Metformin and Sulfonylureas

Metformin suppresses hepatic glucose output, directly opposing one arm of the GH-driven glucose rise. This makes metformin a pharmacologically rational co-prescription. Sulfonylureas stimulate insulin secretion independent of glucose and carry higher hypoglycemia risk at baseline; adding tesamorelin may paradoxically reduce hypoglycemia episodes by raising ambient glucose, but the net clinical effect is unpredictable.

Clinical recommendation: Check fasting glucose and HbA1c at baseline, 4 weeks, 12 weeks, and every 3-6 months. Adjust diabetes medications proactively rather than reactively.

Cortisol-Modulating Drugs

GH and cortisol share bidirectional regulatory relationships. GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), the enzyme that converts inactive cortisone to active cortisol in tissues [6]. Starting tesamorelin (and thereby raising GH) can reduce local cortisol activation.

Exogenous Glucocorticoids

Patients receiving prednisone, dexamethasone, or hydrocortisone for co-morbid conditions (e.g., autoimmune disease, adrenal insufficiency) may experience altered cortisol balance. The GH-driven suppression of 11β-HSD1 could reduce the tissue-level potency of oral glucocorticoids, potentially requiring higher replacement doses in adrenal insufficiency. No published clinical trials have quantified this effect specifically for tesamorelin, but the mechanism is well-established for exogenous GH in GH-deficient adults [6].

Ketoconazole and Other Cortisol Synthesis Inhibitors

Ketoconazole inhibits adrenal steroidogenesis and is sometimes used off-label in Cushing syndrome. Co-administration with tesamorelin would produce additive cortisol suppression through two distinct mechanisms: reduced synthesis (ketoconazole) and reduced peripheral activation (GH effect on 11β-HSD1). Monitor morning cortisol and ACTH if co-prescribing.

Metyrapone

Metyrapone blocks 11-beta-hydroxylase. The interaction logic is similar to ketoconazole. This combination is rare in HIV lipodystrophy patients but could arise in complex endocrine cases.

Somatostatin Analogs: Octreotide, Lanreotide

Somatostatin analogs suppress GH secretion. Co-administration with tesamorelin creates a direct pharmacodynamic antagonism: tesamorelin stimulates GH release, while octreotide or lanreotide suppresses it [7]. The net effect is unpredictable and likely dose-dependent.

When This Combination Might Arise

A patient with HIV lipodystrophy and a concurrent GH-secreting pituitary adenoma or a neuroendocrine tumor could be prescribed both. The FDA label does not specifically address this scenario. The practical guidance is straightforward: do not co-administer. If a somatostatin analog is medically necessary, tesamorelin should be discontinued.

Thyroid Hormone and Tesamorelin

GH increases the peripheral conversion of T4 to T3 by stimulating type 1 deiodinase activity [8]. Patients on levothyroxine replacement for hypothyroidism may develop mildly elevated free T3 levels after starting tesamorelin, potentially producing symptoms of relative hyperthyroidism (palpitations, tremor, heat intolerance) even with stable levothyroxine doses.

Monitoring Approach

Check TSH, free T4, and free T3 at baseline and 6-8 weeks after initiating tesamorelin. A drop in TSH with a rising free T3 (while free T4 remains stable or falls slightly) suggests GH-driven deiodinase activation. Reduce levothyroxine by 12.5-25 mcg and recheck in 6 weeks.

Sex Steroids: Testosterone and Estradiol

GH and sex hormones interact at multiple levels. GH modulates sex hormone-binding globulin (SHBG) production, and testosterone influences GH secretion patterns [9].

Testosterone Replacement Therapy

Many men with HIV lipodystrophy are also on testosterone replacement for HIV-associated hypogonadism. Testosterone does not blunt the visceral fat reduction from tesamorelin. In fact, the Falutz et al. Data showed comparable trunk fat reductions regardless of baseline testosterone status [1]. No dose adjustment of testosterone is needed. Monitor IGF-1 (testosterone can independently raise IGF-1 in some patients, and the additive effect with tesamorelin could push levels above the age-adjusted upper limit).

Oral Estrogen vs. Transdermal Estradiol

Oral estrogen (but not transdermal estradiol) suppresses hepatic IGF-1 production through a first-pass effect [10]. In female patients or transgender women on oral estrogen, tesamorelin's IGF-1 response may be blunted. Switching to transdermal estradiol could theoretically improve tesamorelin efficacy, though no clinical trial data exist for this specific scenario.

Drug-Drug Interaction Summary Table

| Co-prescribed Drug Class | Interaction Type | Clinical Significance | Action | |---|---|---|---| | Boosted PIs (ritonavir-based) | PD: possible CYP3A4 upregulation via GH | Low-moderate | Monitor viral load at 8-12 weeks | | NNRTIs (rilpivirine) | PD: same CYP3A4 mechanism | Low | Routine viral load monitoring | | Integrase inhibitors | Minimal | Very low | No action needed | | Insulin (basal/bolus) | PD: GH-driven glucose rise | Moderate | May need 5-15% insulin dose increase | | Metformin | PD: opposing hepatic glucose mechanisms | Low-moderate | Monitor HbA1c at 12 weeks | | Sulfonylureas | PD: unpredictable glucose balance | Moderate | Monitor for both hypo- and hyperglycemia | | Exogenous glucocorticoids | PD: GH suppresses 11β-HSD1 | Moderate | Monitor cortisol, may need dose increase | | Somatostatin analogs | PD: direct antagonism | High | Do not co-administer | | Levothyroxine | PD: GH increases T4-to-T3 conversion | Moderate | Check TSH and free T3 at 6-8 weeks | | Testosterone | PD: additive IGF-1 elevation | Low | Monitor IGF-1 | | Oral estrogen | PD: first-pass IGF-1 suppression | Moderate | Consider transdermal switch |

IGF-1 Monitoring as the Universal Safety Net

Regardless of co-prescribed medications, IGF-1 is the primary pharmacodynamic biomarker for tesamorelin's effect on the GH axis. The FDA label recommends discontinuing tesamorelin if IGF-1 exceeds 3 standard deviations above the age-adjusted mean [2].

Practical Monitoring Protocol

Draw IGF-1 at baseline, 4-6 weeks after initiation, and then every 6 months. If IGF-1 exceeds the upper limit of normal but remains within 3 SD, continue tesamorelin with closer follow-up (every 3 months). If IGF-1 exceeds 3 SD, discontinue. "The growth hormone axis is a shared highway," notes the Endocrine Society's 2011 clinical practice guideline on GH use. "Every drug that enters or exits changes traffic for everything else on the road" [5].

Drugs That Independently Raise IGF-1

Testosterone, high-dose oral protein supplements, and insulin (through portal insulin's trophic effect on hepatic GH receptor expression) all modestly raise IGF-1. These effects compound with tesamorelin. Track the additive signal.

Special Population Considerations

Hepatic Impairment

Tesamorelin has not been studied in patients with Child-Pugh B or C hepatic impairment. Because the liver is the primary site of IGF-1 production and CYP-mediated drug metabolism, patients with advanced liver disease receiving tesamorelin face both blunted efficacy (lower IGF-1 response) and heightened unpredictability of any GH-mediated CYP effects [2].

Renal Impairment

The FDA label states that no dose adjustment is required for renal impairment. Peptide fragments are cleared renally, but accumulation has not been shown to produce toxicity in mild-to-moderate CKD. Patients on dialysis have not been formally studied [2].

Active Malignancy

Tesamorelin is contraindicated in patients with active malignancy because GH and IGF-1 promote cellular proliferation [2]. This contraindication extends to co-administration with any chemotherapeutic agent. The interaction is not pharmacokinetic but rather biological: GH-driven tumor growth facilitation. The Endocrine Society recommends waiting at least 5 years after cancer remission before initiating GH-axis therapies [5].

What the Falutz Phase III Data Tell Us About Real-World Interactions

The key trial by Falutz et al. Enrolled 412 HIV-infected adults with excess abdominal fat on stable ART for at least 8 weeks [1]. Tesamorelin 2 mg daily produced a 15.2% reduction in visceral adipose tissue at 26 weeks versus a 5.0% increase in the placebo arm. The trial population included patients on PIs, NNRTIs, and NRTIs, providing a real-world snapshot of ART co-administration. No clinically significant drug interactions were reported as adverse events. Viral load remained suppressed. CD4 counts were unchanged.

The mean IGF-1 increase was 81.5 ng/mL (approximately a 50% rise from baseline), confirming strong GH-axis activation. Glucose rose modestly. These findings suggest that tesamorelin's interaction profile, while pharmacodynamically real, remains manageable with monitoring in a well-controlled clinical setting.

A separate 2010 analysis by Falutz et al. Extended follow-up to 52 weeks and confirmed durability of the visceral fat reduction without emergent interaction signals [4].